Pharmaceuticals and Life Sciences Pharmaceuticals and Life Sciences

Definium Therapeutics, Inc. in its approximately US$805-million public offering

On June 25, 2026, Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, closed its approximately US$805-million public offering, which included a full...

Lead Office: Vancouver Date Announced: June 25, 2026 Value: US$805 million

Certek Group in its acquisition of JSS Medical Research Inc.

On June 5, 2026, Certek Group announced its acquisition of JSS Medical Research Inc., which closed in May 2026. Certek is an international provider of specialist testing, inspection, certification and compliance (TICC) services, delivering mission-critical compliance solutions to clients across...

Lead Office: Montreal Date Announced: June 5, 2026 Value: --

Biossil Inc. in its US$43-million financing round

On April 21, 2026, Biossil Inc. announced its US$43-million financing round co-led by Founders Fund and OpenAI. The financing will be used to support the company’s mission of offering previously failed drugs a chance to advance to approval at a fraction of traditional cost and...

Lead Office: Toronto Date Announced: April 21, 2026 Value: US$43 million

Medici Technologies Inc. (dba Livewell) in its sale to Hims & Hers

On December 4, 2025, Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, announced its expansion into Canada through its acquisition of Medici Technologies Inc. (dba Livewell). Livewell is a trusted Canadian digital health platform focused...

Lead Office: Montreal Date Announced: December 4, 2025 Value: --

Morphocell Technologies Inc. in its completion of US$50-million Series A

On December 2, 2025, Morphocell Technologies Inc. announced it completed US$50-million Series A financing following a US$10-million add-on led by Investissement Québec. Morphocell Technologies Inc. is a biotechnology company. Osler, Hoskin & Harcourt LLP advised Morphocell Technologies...

Lead Office: Montreal Date Announced: December 2, 2025 Value: US$50 million

Mind Medicine in its $249-million underwritten public offering

On November 3, 2025, Mind Medicine, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced it closed approximately a $249-million underwritten public offering which includes a full exercise of the underwriter’s option to purchase...

Lead Office: Vancouver Date Announced: November 3, 2025 Value: $249 million

AmacaThera in its licensing agreement with Pacira Biosciences for US$230 million

On November 4, 2025, AmacaThera announced that it signed an exclusive global licensing agreement with Pacira Biosciences for up to US$230 million, validating its tunable drug delivery platform. AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a...

Lead Office: Toronto Date Announced: November 4, 2025 Value: US$230 million

Genesys Capital in connection with Antegrade Medical’s $7.3-million Series Seed financing

On October 28, 2025,  Antegrade Medical Inc. announced the closing of a $7.3-million Series Seed financing. The financing was led by Sectoral Asset Management and had participation from Genesys Capital, Desjardins Capital, Seido Capital and private investors. Genesys Capital invests in and...

Lead Office: Toronto Date Announced: October 28, 2025 Value: $7.3 million

Aspect Biosystems in its $115-million Series B funding round

On January 8, 2025, Aspect Biosystems announced the closing of its $115-million Series B funding round led by Dimension, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea...

Lead Office: Vancouver Date Announced: January 8, 2025 Value: $115 million

Amplitude Ventures and Lifearc Ventures in connection with Fluid Biomed's $27-million financing

On December 16, 2024, Fluid Biomed announced the close of its $27-million Series A funding round co-led by Amplitude Ventures and an undisclosed investor, with follow-up investment from LifeArc Ventures. Fluid Biomed plans to use the funds to fuel the development of its innovative stent for brain...

Lead Office: Calgary Date Announced: December 16, 2024 Value: $27 million